Urokinase for acute ischemic stroke within 6 hours
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether the clot-busting drug urokinase can help people who have had an ischemic stroke (a stroke caused by a blood clot). The goal is to dissolve the clot and improve recovery, as long as treatment starts within 6 hours of the first symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You were diagnosed with an ischemic stroke (a stroke from a blood clot) and treatment can start within 6 hours of when symptoms began.
- Your stroke symptoms have lasted at least 30 minutes and haven't improved much.
- You have a certain level of disability from the stroke (NIHSS score of 1 or more) but not so severe that it would be risky.
- You are not at high risk for bleeding — for example, no recent bleeding, no blood clotting problems, and not on strong blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a drug called human urinary kallidinogenase (HUK) can improve recovery for people who have had a stroke and already received clot-busting medicine or a procedure to remove the clot. The goal is to see if it helps reduce disability after a stroke.
This study looks at how well the clot-busting drug urokinase works for treating acute ischemic stroke in everyday medical practice. It may help if you have had a stroke and are eligible for clot-dissolving medication.
This trial tests a clot-busting drug called recombinant human prourokinase for people having an ischemic stroke (a stroke from a blocked blood vessel). The drug is given through an IV within 4.5 hours of symptoms to help restore blood flow and potentially reduce disability.
This trial tests a clot-dissolving medication (pro-urokinase) for people with recent strokes in the back of the brain. You would be treated 4.5 to 9 hours after symptoms start, which is beyond the typical treatment window, using special MRI patterns to identify patients most likely to benefit.
This trial tests giving a second dose of an IV clot-dissolving medicine (prourokinase) to patients who had a stroke from a large clot but didn't improve enough after the first dose. The goal is to see if a second dose within 6 hours of stroke onset can help more patients recover.
This trial tests whether adding a drug called human urinary kallidinogenase to standard clot-busting therapy with reteplase improves outcomes for people having a first or recurrent ischemic stroke. It is designed for patients who can start treatment within 4.5 hours of symptoms and have moderate stroke severity.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.